Bortezomib For
Found 7 free book(s)
DARATUMUMAB WITH BORTEZOMIB, THALIDOMIDE AND …
nssg.oxford-haematology.org.ukBortezomib 1.3 mg/m2 given SC bolus Days 1, 8, 15 and 22 Thalidomide 50 -100 mg PO (preferably nocte) Start at 50mg and increase as tolerated Daily Dexamethasone 40 mg PO (this includes dexamethasone pre-meds) i.e. on daratumumab days, 20mg is to be administered in addition to the 20mg pre-med
DRUG NAME: Bortezomib - BC Cancer
www.bccancer.bc.caBortezomib is a reversible inhibitor of the 26S proteasome, a protein complex that degrades ubiquitinated proteins. This inhibition affects cancer cells in a number of ways, including altering regulatory proteins, which control cell cycle progression and Nuclear Factor kappa B activation. Inhibition of the proteasome results in cell cycle ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euPatients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table1 (see section4.4). Patients with pre-existing severe neuropathy may be treated withVELCADE only after careful risk/benefit assessment. Table1: Recommended* posology modifications for bortezomib-related neuropathy
Daratumumab, bortezomib & dexamethasone (DVd)
www.swagcanceralliance.nhs.ukBortezomib: withhold for grade 3 non-haematological or grade 4 haematological toxicities. Once toxicity has resolved, re-initiate at reduced dose (1.3 mg/m2 reduced to 1.0 mg/m2; 1.0 mg/m2 reduced to 0.7 mg/m2). If the toxicity is not resolved or if it recurs at the lowest dose, discontinue unless benefit outweighs risk. Renal impairment
Prescribing Information | VELCADE® (bortezomib)
www.velcade.comVELCADE® (bortezomib) for injection, for subcutaneous or intravenous use Initial U.S. Approval: 2003 -----INDICATIONS AND USAGE----- VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma (1.1) treatment of adult patients with mantle cell lymphoma (1.2)
BC Cancer Protocol Summary for the Treatment of Multiple ...
www.bccancer.bc.ca• The last bortezomib and cyclophosphamide dose should be given at least 14 days prior to stem cell collection. • Platelet count less than 30 x 10. 9 /L may require transfusion support • If absolute neutrophil count (ANC) less than 0.5 x 10: 9 /L may require giving filgrastim :
BORTEZOMIB THALIDOMIDE AND DEXAMETHASONE …
nssg.oxford-haematology.org.ukbortezomib dose At least 72 hours should elapse between consecutive doses of bortezomib. Bortezomib can also be administered weekly on days 1, 8 and 15 in a 21 days cycle in selected patients. If neurotoxicity precludes completing planned therapy, consider completing the intended number of VTD cycles after the autologous transplant.